Ucb, Inc.
Smyrna, GA Doing business as UCB Pharma, Inc.
- UEI
- F3N9Q9TY2BC9
- CAGE
- 0S423
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1950 Lake Park Dr SE, Smyrna, GA 30080, USA
- Website
- ucb.com
- Founded
- 1928
- Employees
- 5K-10K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $370,495 |
| FY2025 | $369,799 |
| FY2024 | $92,825 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $370,495 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Injectable drug for a veteran | Veterans Integrated Service Network 5 (VHA) | $31,041 | |
| Zilbrysq 32.4 MG | Veterans Integrated Service Network 5 (VHA) | $31,041 | |
| Zilbrysq 32.4 MG | Veterans Integrated Service Network 5 (VHA) | $31,041 | |
| Zilbrysq 32.4 MG | Veterans Integrated Service Network 5 (VHA) | $31,041 | |
| Zilbrysq 32.4 MG | Veterans Integrated Service Network 5 (VHA) | $31,041 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Kiniksa Pharmaceuticals (Uk), LTD. | England | 325412 Pharmaceutical Preparation Manufacturing |
| Jazz Pharmaceuticals, Inc. | Menlo Park, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Argenx US, Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Genzyme | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Ucb, Inc., doing business as UCB Pharma, Inc., is a global biopharmaceutical company based in Smyrna, Georgia, that manufactures and supplies injectable and oral neurological and immunological prescription medications to the Department of Veterans Affairs as a prime contractor on the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The company operates exclusively as a prime — 100% of its recent federal awards are prime contracts or indefinite delivery vehicles — competing on full-and-open, firm fixed-price vehicles with no set-aside designations.
UCB Pharma's federal footprint is narrowly concentrated in VA pharmaceutical procurement across a portfolio of $2.6 billion in combined potential value. The Department of Veterans Affairs accounts for 100% of awards: Veterans Integrated Service Network 12 anchors the dollars at $1.98 billion across four awards, while the VA's National Acquisition Center holds $613.2 million across three awards (the two largest single vehicles). VISN 5 and VISN 20 account for the remaining awards but represent only $833 thousand in total obligated spend across the portfolio. All awards operate under the Pharmaceuticals and Drugs FSS-61-IB schedule with pre-negotiated pricing; place of performance is Pittsburgh, Pennsylvania, with product distribution to VA facilities nationwide.
UCB Pharma's primary vehicle is a $1.11 billion Federal Supply Schedule contract awarded September 15, 2025, through September 14, 2030, covering Zilbrysq (the company's flagship injectable neurological treatment), Fintepla, Kygevvi, Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra. A single-award Blanket Purchase Agreement worth $3.84 million was awarded October 31, 2025, through October 30, 2027, also covering Fintepla and Zilbrysq. Recent delivery orders under these vehicles include five orders from VISN 5 (March through August 2026) for Zilbrysq 32.4 mg at $31,040.96 each, a $371.2 thousand order from VISN 20 in October 2025 for Zilbrysq with 2026 price adjustment, and a $214.2 thousand bulk Zilbrysq order from VISN 20 in October 2024. Activity has grown from one award in 2022 to five in 2026, though this trajectory reflects the award of the large FSS-61-IB vehicle in September 2025 and the BPA in October 2025; one award (the $371 thousand VISN 20 BPA delivery order) reaches ultimate completion within the next twenty-four months and faces recompete exposure. The vendor holds no subcontract relationships in the source data.
Quick answers
Is Ucb, Inc. registered in SAM.gov?
Yes. Ucb, Inc.'s SAM.gov registration is active through May 11, 2027.
What is Ucb, Inc.'s CAGE code?
Ucb, Inc.'s CAGE code is 0S423, and its Unique Entity ID (UEI) is F3N9Q9TY2BC9.
Which contract vehicles does Ucb, Inc. hold?
Ucb, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Ucb, Inc. received in federal contracts?
Federal contracts obligated $369,799 to Ucb, Inc. in fiscal year 2025 and $833,119 in fiscal years 2023 through 2027.
What is Ucb, Inc.'s most recent federal award?
Ucb, Inc.'s most recent federal contract award is Injectable drug for a veteran (36C24526F0346), from Veterans Integrated Service Network 5 (VHA), on August 6, 2026.
On GovTribe
See Ucb, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors